Brookline Capital Management Predicts CRBU FY2029 Earnings

Caribou Biosciences, Inc. (NASDAQ:CRBU) – Equities research analysts at Brookline Capital Management issued their FY2029 earnings per share estimates for Caribou Biosciences in a research note issued to investors on Monday, January 6th. Brookline Capital Management analyst L. Cann forecasts that the company will post earnings of $16.92 per share for the year. The consensus estimate for Caribou Biosciences’ current full-year earnings is ($1.64) per share.

CRBU has been the subject of several other reports. HC Wainwright restated a “buy” rating and issued a $9.00 price objective on shares of Caribou Biosciences in a report on Friday, November 15th. Bank of America lowered their target price on Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating for the company in a research note on Tuesday. Finally, Citigroup decreased their price objective on Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating for the company in a report on Tuesday, November 26th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $10.33.

Caribou Biosciences Trading Down 0.5 %

Shares of CRBU opened at $1.87 on Wednesday. Caribou Biosciences has a 1-year low of $1.50 and a 1-year high of $8.33. The firm’s 50-day moving average price is $2.03 and its 200-day moving average price is $2.00. The firm has a market capitalization of $169.33 million, a price-to-earnings ratio of -1.13 and a beta of 2.34.

Caribou Biosciences (NASDAQ:CRBU) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.06. Caribou Biosciences had a negative net margin of 1,290.81% and a negative return on equity of 45.46%. The business had revenue of $2.02 million for the quarter, compared to analysts’ expectations of $3.37 million.

Institutional Trading of Caribou Biosciences

Hedge funds and other institutional investors have recently made changes to their positions in the stock. PFM Health Sciences LP boosted its holdings in Caribou Biosciences by 5.5% in the third quarter. PFM Health Sciences LP now owns 4,306,671 shares of the company’s stock worth $8,441,000 after acquiring an additional 223,299 shares in the last quarter. Dimensional Fund Advisors LP raised its position in shares of Caribou Biosciences by 25.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,623,283 shares of the company’s stock worth $4,302,000 after purchasing an additional 536,162 shares during the last quarter. Geode Capital Management LLC boosted its stake in Caribou Biosciences by 6.5% in the 3rd quarter. Geode Capital Management LLC now owns 2,030,443 shares of the company’s stock worth $3,980,000 after purchasing an additional 124,782 shares in the last quarter. FMR LLC grew its position in Caribou Biosciences by 7.4% during the 3rd quarter. FMR LLC now owns 1,581,493 shares of the company’s stock valued at $3,100,000 after purchasing an additional 109,606 shares during the last quarter. Finally, Renaissance Technologies LLC bought a new stake in Caribou Biosciences during the 2nd quarter valued at about $2,432,000. Hedge funds and other institutional investors own 77.51% of the company’s stock.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.